Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer

Y. Ishii, H. Hasegawa, T. Endo, Koji Okabayashi, H. Ochiai, K. Moritani, M. Watanabe, Yuukou Kitagawa

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Aims: The aim of this study was to evaluate the usefulness of neoadjuvant systemic chemotherapy using irinotecan, 5-FU, and leucovorin (LV) for the treatment of locally advanced rectal cancer, which was a powerful ploychemotherapy in those days in Japan. Methods: Between 2001 and 2004, 26 patients with T3 or T4 and N0-2 non-metastatic resectable rectal cancer were selectively enrolled in this study. Neoadjuvant chemotherapy consisted of two cycles of irinotecan (80 mg/m2), 5-FU (500 mg/m2), and LV (250 mg/m2) on days 1, 8, and 15 for 4 weeks. Surgical resection was performed in all the patients 2-4 weeks after the completion of chemotherapy. Results: Overall down-staging was observed in 15 patients. T level and N level down-staging were observed in 12 and 13 patients, respectively. A pathological complete response was observed in one patients. The median follow-up period was 75 months (range, 8-97 months). Recurrences occurred in 5 patients including pelvic relapses in 3 and distant metastases in 2. The 5-year relapse-free and overall survival rates were 74% and 84%, respectively. Conclusions: Neoadjuvant systemic chemotherapy comprised of a combination of multi-drugs as irinotecan, 5-FU, and LV may be beneficial to the prognoses of patients with locally advanced rectal cancer.

Original languageEnglish
Pages (from-to)1061-1065
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume36
Issue number11
DOIs
Publication statusPublished - 2010 Nov

Fingerprint

irinotecan
Leucovorin
Rectal Neoplasms
Fluorouracil
Drug Therapy
Recurrence
Drug Combinations

Keywords

  • 5-Fluorouracil
  • Irinotecan
  • Leucovorin
  • Medium-term results
  • Neoadjuvant systemic chemotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Medicine(all)

Cite this

Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. / Ishii, Y.; Hasegawa, H.; Endo, T.; Okabayashi, Koji; Ochiai, H.; Moritani, K.; Watanabe, M.; Kitagawa, Yuukou.

In: European Journal of Surgical Oncology, Vol. 36, No. 11, 11.2010, p. 1061-1065.

Research output: Contribution to journalArticle

@article{7c771b2eace7410d899c1ac8315a5ba4,
title = "Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer",
abstract = "Aims: The aim of this study was to evaluate the usefulness of neoadjuvant systemic chemotherapy using irinotecan, 5-FU, and leucovorin (LV) for the treatment of locally advanced rectal cancer, which was a powerful ploychemotherapy in those days in Japan. Methods: Between 2001 and 2004, 26 patients with T3 or T4 and N0-2 non-metastatic resectable rectal cancer were selectively enrolled in this study. Neoadjuvant chemotherapy consisted of two cycles of irinotecan (80 mg/m2), 5-FU (500 mg/m2), and LV (250 mg/m2) on days 1, 8, and 15 for 4 weeks. Surgical resection was performed in all the patients 2-4 weeks after the completion of chemotherapy. Results: Overall down-staging was observed in 15 patients. T level and N level down-staging were observed in 12 and 13 patients, respectively. A pathological complete response was observed in one patients. The median follow-up period was 75 months (range, 8-97 months). Recurrences occurred in 5 patients including pelvic relapses in 3 and distant metastases in 2. The 5-year relapse-free and overall survival rates were 74{\%} and 84{\%}, respectively. Conclusions: Neoadjuvant systemic chemotherapy comprised of a combination of multi-drugs as irinotecan, 5-FU, and LV may be beneficial to the prognoses of patients with locally advanced rectal cancer.",
keywords = "5-Fluorouracil, Irinotecan, Leucovorin, Medium-term results, Neoadjuvant systemic chemotherapy, Rectal cancer",
author = "Y. Ishii and H. Hasegawa and T. Endo and Koji Okabayashi and H. Ochiai and K. Moritani and M. Watanabe and Yuukou Kitagawa",
year = "2010",
month = "11",
doi = "10.1016/j.ejso.2010.05.017",
language = "English",
volume = "36",
pages = "1061--1065",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer

AU - Ishii, Y.

AU - Hasegawa, H.

AU - Endo, T.

AU - Okabayashi, Koji

AU - Ochiai, H.

AU - Moritani, K.

AU - Watanabe, M.

AU - Kitagawa, Yuukou

PY - 2010/11

Y1 - 2010/11

N2 - Aims: The aim of this study was to evaluate the usefulness of neoadjuvant systemic chemotherapy using irinotecan, 5-FU, and leucovorin (LV) for the treatment of locally advanced rectal cancer, which was a powerful ploychemotherapy in those days in Japan. Methods: Between 2001 and 2004, 26 patients with T3 or T4 and N0-2 non-metastatic resectable rectal cancer were selectively enrolled in this study. Neoadjuvant chemotherapy consisted of two cycles of irinotecan (80 mg/m2), 5-FU (500 mg/m2), and LV (250 mg/m2) on days 1, 8, and 15 for 4 weeks. Surgical resection was performed in all the patients 2-4 weeks after the completion of chemotherapy. Results: Overall down-staging was observed in 15 patients. T level and N level down-staging were observed in 12 and 13 patients, respectively. A pathological complete response was observed in one patients. The median follow-up period was 75 months (range, 8-97 months). Recurrences occurred in 5 patients including pelvic relapses in 3 and distant metastases in 2. The 5-year relapse-free and overall survival rates were 74% and 84%, respectively. Conclusions: Neoadjuvant systemic chemotherapy comprised of a combination of multi-drugs as irinotecan, 5-FU, and LV may be beneficial to the prognoses of patients with locally advanced rectal cancer.

AB - Aims: The aim of this study was to evaluate the usefulness of neoadjuvant systemic chemotherapy using irinotecan, 5-FU, and leucovorin (LV) for the treatment of locally advanced rectal cancer, which was a powerful ploychemotherapy in those days in Japan. Methods: Between 2001 and 2004, 26 patients with T3 or T4 and N0-2 non-metastatic resectable rectal cancer were selectively enrolled in this study. Neoadjuvant chemotherapy consisted of two cycles of irinotecan (80 mg/m2), 5-FU (500 mg/m2), and LV (250 mg/m2) on days 1, 8, and 15 for 4 weeks. Surgical resection was performed in all the patients 2-4 weeks after the completion of chemotherapy. Results: Overall down-staging was observed in 15 patients. T level and N level down-staging were observed in 12 and 13 patients, respectively. A pathological complete response was observed in one patients. The median follow-up period was 75 months (range, 8-97 months). Recurrences occurred in 5 patients including pelvic relapses in 3 and distant metastases in 2. The 5-year relapse-free and overall survival rates were 74% and 84%, respectively. Conclusions: Neoadjuvant systemic chemotherapy comprised of a combination of multi-drugs as irinotecan, 5-FU, and LV may be beneficial to the prognoses of patients with locally advanced rectal cancer.

KW - 5-Fluorouracil

KW - Irinotecan

KW - Leucovorin

KW - Medium-term results

KW - Neoadjuvant systemic chemotherapy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=77957880951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957880951&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2010.05.017

DO - 10.1016/j.ejso.2010.05.017

M3 - Article

C2 - 20538422

AN - SCOPUS:77957880951

VL - 36

SP - 1061

EP - 1065

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 11

ER -